<DOC>
	<DOCNO>NCT00744250</DOCNO>
	<brief_summary>The purpose research study learn activity oral Pancrecarb® ( pancreatic enzyme preparation contain protein help digest food ) , administer mouth capsule fill specially coated granule patient take exogenous pancreatic enzyme therapy . Specific enzymes activity determine sample stomach intestinal fluid standard liquid meal .</brief_summary>
	<brief_title>Intraduodenal Aspiration Study Assess Bioavailability Oral Pancrecarb® Compared Placebo Control</brief_title>
	<detailed_description>Purpose : The purpose study assess bioavailability oral Pancrecarb® ( exogenous pancreatic enzyme administer orally capsule fill enteric coat granule ) compare placebo control patient pancreatic insufficiency . Lipase , amylase protease activity determine stomach duodenal aspirate standard meal stimulation . Participants : Patients pancreatic insufficiency recruit study population . Procedures ( method ) : Eligible subject undergo initial screen phase provide stool sample confirm pancreatic exocrine insufficiency base spot fecal elastase-1 &lt; 75 mcg/g stool . Within one month screen phase , subject meet inclusion criterion schedule arrive GCRC 7pm . If subject female child bear age , serum pregnancy test check . At 7am subject escort fluoroscopy placement oro-enteric tube . Once tip tube position duodenum , subject escort back GCRC . Prior administration capsule liquid diet , baseline gastric duodenal secretion aspirate via oro-enteric tube investigator . Subjects receive 5 capsule active drug standard liquid Lundh diet 360 mL 10 minute period , administer simulate fed state . Then duodenal gastric secretion aspirate tube 3-hour period . At end 3 hour , subject allow rest 60 minute . The second phase consist 5 capsule placebo standard liquid Lundh diet , another 3-hour aspiration phase . After second 3-hour aspiration period , balloon deflate tube remove . Subjects observe 30 minute discharge .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Pancreatitis</mesh_term>
	<mesh_term>Pancreatitis , Chronic</mesh_term>
	<mesh_term>Exocrine Pancreatic Insufficiency</mesh_term>
	<mesh_term>Pancrelipase</mesh_term>
	<mesh_term>Pancreatin</mesh_term>
	<criteria>Documented pancreatic enzyme insufficiency determine spot fecal elastase1 ( &lt; 75 mcg/g ) time screen Required daily exogenous enzyme supplementation commercially available pancreatic enzyme ≥ 18 year age Male female subject Able swallow capsule Clinically stable evidence acute medical condition History fibrosing colonopathy cystic fibrosis subject Current diagnosis history distal intestinal obstruction syndrome ( DIOS ) past 4 month Known contraindication , sensitivity hypersensitivity porcine pancreatic enzyme , benzocaine similar product Women positive serum betahCG time screen day study ( due radiation exposure ) Liver disease ALT AST ≥ 3 time upper limit normal Bilirubin ≥ 3 time upper limit normal Acute pancreatitis acute exacerbation chronic pancreatitis within 90 day Use medication affect intestinal transit ( example , narcotic , erythromycin , metoclopramide etc . ) Subjects receive treatment antacid , H2 receptor blocker , proton pump inhibitor unable discontinue within 72 hr prior study day Diabetes mellitus A medical condition investigator deem significant enough interfere ability subject participate intubation study interfere assessment enzyme bioavailability Small bowel disease ( i.e . celiac disease ) Lactose intolerance History gastric resection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>Exocrine Pancreatic Insufficiency</keyword>
	<keyword>Chronic Pancreatitis</keyword>
	<keyword>Cystic fibrosis</keyword>
	<keyword>Pancrelipase</keyword>
	<keyword>Pancrecarb</keyword>
	<keyword>Intraduodenal aspiration</keyword>
	<keyword>Bioavailability</keyword>
</DOC>